keyword
MENU ▼
Read by QxMD icon Read
search

ranolazine

keyword
https://www.readbyqxmd.com/read/28521025/mechanism-of-as2o3-induced-action-potential-prolongation-and-using-hips-cms-to-evaluate-the-rescue-efficacy-of-drugs-with-different-rescue-mechanism
#1
Meng Yan, Lifang Feng, Yanhui Shi, Junnan Wang, Yan Liu, Fengmei Li, Baoxin Li
Arsenic trioxide (As2O3) has been verified as a breakthrough in the management of acute promyelocytic leukemia in recent decades. However, cardiotoxicity, especially long QT syndrome (LQTS) has become the most important issue during As2O3 treatment. The characterized mechanisms behind this adverse effect are inhibition of cardiac hERG channel trafficking and increase of cardiac calcium currents. In our study, we found a new pathway underlying As2O3-induced cardiotoxicity that As2O3 accelerates lysosomal degradation of hERG on plasma membrane after using brefeldin A (BFA) to block protein trafficking...
May 17, 2017: Toxicological Sciences: An Official Journal of the Society of Toxicology
https://www.readbyqxmd.com/read/28497941/antiarrhythmic-effects-of-ranolazine-used-both-alone-for-prevention-of-atrial-fibrillation-and-as-an-add-on-to-intravenous-amiodarone-for-its-pharmacological-cardioversion-a-meta-analysis
#2
Renato DE Vecchis, Carmelina Ariano, Anna Giasi, Carmela Cioppa
BACKGROUND: Recent evidence from relatively small randomized controlled trials would seem to support a useful role of ranolazine for the prevention and treatment of atrial fibrillation (AF). The present study is aimed at providing information about the possible beneficial anti-arrhythmic properties of ranolazine. In particular, the meta-analysis carried out in this study focuses on the application of ranolazine to prophylaxis and treatment of atrial fibrillation. METHODS: Both randomized controlled trials (RCTs) and non randomized observational studies concerning the effects of ranolazine on AF were included in the meta-analysis...
May 10, 2017: Minerva Cardioangiologica
https://www.readbyqxmd.com/read/28491780/complexity-of-ranolazine-and-phenytoin-use-in-an-infant-with-long-qt-syndrome-type-3
#3
Reina Bianca Tan, Sujata Chakravarti, Melissa Busovsky-McNeal, Abigail Walsh, Frank Cecchin
No abstract text is available yet for this article.
January 2017: HeartRhythm Case Reports
https://www.readbyqxmd.com/read/28473655/lipid-catabolism-inhibition-sensitizes-prostate-cancer-cells-to-antiandrogen-blockade
#4
Thomas W Flaig, Maren Salzmann-Sullivan, Lih-Jen Su, Zhiyong Zhang, Molishree Joshi, Miguel A Gijón, Jihye Kim, John J Arcaroli, Adrie Van Bokhoven, M Scott Lucia, Francisco G La Rosa, Isabel R Schlaepfer
Prostate cancer (PCa) is the most common malignancy among Western men and the second leading-cause of cancer related deaths. For men who develop metastatic castration resistant PCa (mCRPC), survival is limited, making the identification of novel therapies for mCRPC critical. We have found that deficient lipid oxidation via carnitine palmitoyltransferase (CPT1) results in decreased growth and invasion, underscoring the role of lipid oxidation to fuel PCa growth. Using immunohistochemistry we have found that the CPT1A isoform is abundant in PCa compared to benign tissue (n=39, p<0...
April 21, 2017: Oncotarget
https://www.readbyqxmd.com/read/28473401/ranolazine-in-symptomatic-diabetic-patients-without-obstructive-coronary-artery-disease-impact-on-microvascular-and-diastolic-function
#5
Nishant R Shah, Michael K Cheezum, Vikas Veeranna, Stephen J Horgan, Viviany R Taqueti, Venkatesh L Murthy, Courtney Foster, Jon Hainer, Karla M Daniels, Jose Rivero, Amil M Shah, Peter H Stone, David A Morrow, Michael L Steigner, Sharmila Dorbala, Ron Blankstein, Marcelo F Di Carli
BACKGROUND: Treatments for patients with myocardial ischemia in the absence of angiographic obstructive coronary artery disease are limited. In these patients, particularly those with diabetes mellitus, diffuse coronary atherosclerosis and microvascular dysfunction is a common phenotype and may be accompanied by diastolic dysfunction. Our primary aim was to determine whether ranolazine would quantitatively improve exercise-stimulated myocardial blood flow and cardiac function in symptomatic diabetic patients without obstructive coronary artery disease...
May 4, 2017: Journal of the American Heart Association
https://www.readbyqxmd.com/read/28473137/ranolazine-in-diabetics-with-stable%C3%A2-ischemic-heart-disease-greatest-efficacy-related-to-greatest-metabolic-stress
#6
EDITORIAL
Peter H Stone
No abstract text is available yet for this article.
May 9, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28473136/ranolazine-after-incomplete-percutaneous-coronary-revascularization-in-patients-with-versus-without-diabetes-mellitus-river-pci-trial
#7
Alexander C Fanaroff, Stefan K James, Giora Weisz, Kristi Prather, Kevin J Anstrom, Daniel B Mark, Ori Ben-Yehuda, Karen P Alexander, Gregg W Stone, E Magnus Ohman
BACKGROUND: Chronic angina is more common in patients with diabetes mellitus (DM) with poor glucose control. Ranolazine both treats chronic angina and improves glucose control. OBJECTIVES: This study sought to examine ranolazine's antianginal effect in relation to glucose control. METHODS: The authors performed a secondary analysis of the RIVER-PCI (Ranolazine in Patients with Incomplete Revascularization after Percutaneous Coronary Intervention) trial, a clinical trial in which 2,604 patients with chronic angina and incomplete revascularization following percutaneous coronary intervention were randomized to ranolazine versus placebo...
May 9, 2017: Journal of the American College of Cardiology
https://www.readbyqxmd.com/read/28455610/inhibition-of-late-sodium-current-as-an-innovative-antiarrhythmic-strategy
#8
REVIEW
Philipp Bengel, Shakil Ahmad, Samuel Sossalla
PURPOSE OF REVIEW: Over the last years, evidence is accumulating that enhanced late sodium current (INaL) in cardiac pathologies has fundamental consequences for cellular electrophysiology. This review discusses the underlying mechanisms of INaL-induced arrhythmias and the significance of INaL-inhibition as a possible therapeutic approach. RECENT FINDINGS: Inhibition of enhanced INaL, e.g., by ranolazine, was shown to reverse these effects in different myocardial diseases including heart failure...
April 28, 2017: Current Heart Failure Reports
https://www.readbyqxmd.com/read/28452847/ranolazine-associated-myoclonus
#9
Naveen Trehan, Manmohan Singh, Anupama R Kottam
No abstract text is available yet for this article.
April 25, 2017: American Journal of Therapeutics
https://www.readbyqxmd.com/read/28405132/antianginal-efficacy-and-tolerability-of-ranolazine-as-an-add-on-drug-to-concomitant-medications-primarily-metoprolol-in-chronic-stable-angina-patients-a-prospective-open-label-study
#10
Anant Mahaveer Khot, H V Anuradha, V S Prakash, M C Shivamurathy
OBJECTIVE: To evaluate the efficacy and tolerability of ranolazine as an add-on drug in chronic stable angina patients and the impact of ranolazine on the quality of life in chronic stable angina patients receiving other antianginal medications. MATERIALS AND METHODS: It was a prospective, open-label, hospital-based study involving 144 patients with chronic stable angina. First group received either metoprolol 12.5 or 25 mg/day or other antianginal medications; if the symptoms persist, the dose of metoprolol was increased to 50 mg/day, and to the second group, ranolazine 500 mg BD or 1 g OD was added along with metoprolol or others if the anginal attacks were not subsiding...
January 2017: Journal of Pharmacology & Pharmacotherapeutics
https://www.readbyqxmd.com/read/28368882/ranolazine-therapy-in-drug-refractory-ventricular-arrhythmias
#11
Antonio Curnis, Francesca Salghetti, Manuel Cerini, Enrico Vizzardi, Edoardo Sciatti, Francesca Vassanelli, Clara Villa, Lorenza Inama, Abdallah Raweh, Daniele Giacopelli, Luca Bontempi
AIMS: Ranolazine is an antiischemic and antianginal agent, but experimental and preclinical data provided evidence of additional antiarrhythmic properties. The aim of this study was to evaluate the safety and efficacy of ranolazine in reducing episodes of ventricular arrhythmias in patients with recurrent antiarrhythmic drug-refractory ventricular arrhythmias or with chronic angina. METHODS: Seventeen implantable cardioverter defibrillator (ICD) recipients, who had experienced a worsening of their ventricular arrhythmia burden, and 12 ICD recipients with angina were enrolled...
July 2017: Journal of Cardiovascular Medicine
https://www.readbyqxmd.com/read/28361599/antianginal-therapy-for-stable-ischemic-heart-disease
#12
Santosh K Padala, Michael P Lavelle, Mandeep S Sidhu, Katherine P Cabral, Doralisa Morrone, William E Boden, Peter P Toth
Chronic angina pectoris is associated with considerable morbidity and mortality, especially if treated suboptimally. For many patients, aggressive pharmacologic intervention is necessary in order to alleviate anginal symptoms. The optimal treatment of stable ischemic heart disease (SIHD) should be the prevention of angina and ischemia, with the goal of maximizing both quality and quantity of life. In addition to effective risk factor modification with lifestyle changes, intensive pharmacologic secondary prevention is the therapeutic cornerstone in managing patients with SIHD...
January 1, 2017: Journal of Cardiovascular Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28352365/heart-failure-modulates-electropharmacological-characteristics-of-sinoatrial-nodes
#13
Shih-Lin Chang, Hui-Lun Chuang, Yao-Chang Chen, Yu-Hsun Kao, Yung-Kuo Lin, Yung-Hsin Yeh, Shih-Ann Chen, Yi-Jen Chen
The impact of heart failure (HF) on sinoatrial node (SAN) channel regulation and electropharmacological responses has remained elusive. The present study aimed to investigate the effects of HF on the electrical activity of SANs with and without pharmacological interventions. Action potentials (APs) were recorded in isolated SANs from normal rabbits (control) and those with HF (rapid ventricular pacing for 4 weeks) prior to and after administration of a funny current blocker (ivabradine; 0.1, 0.3, 3 or 10 µM), a calmodulin kinase II inhibitor (KN-93; 0...
February 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/28341360/use-of-antiarrhythmic-medications-in-medicare-part-d-patients-with-an-implantable-cardioverter-defibrillator-and-ventricular-tachycardia
#14
Sean D Pokorney, Xiaojuan Mi, Bradley G Hammill, Nancy M Allen LaPointe, Lesley H Curtis, Sana M Al-Khatib
Ventricular tachycardia (VT) is common in cardiomyopathy patients with an implantable cardioverter-defibrillator. This analysis evaluated antiarrhythmic medication use and change in use over time in patients with VT and structural heart disease. Query of Medicare claims identified patients with an implantable cardioverter-defibrillator and VT. Patients with atrial fibrillation or supraventricular tachycardia were excluded. Two cohorts were created of patients enrolled in Medicare Part D for the 12 months before 2007 and 2012...
May 1, 2017: American Journal of Cardiology
https://www.readbyqxmd.com/read/28320043/effects-of-ranolazine-in-a-model-of-doxorubicin-induced-left-ventricle-diastolic-dysfunction
#15
Donato Cappetta, Grazia Esposito, Raffaele Coppini, Elena Piegari, Rosa Russo, Loreta Pia Ciuffreda, Alessia Rivellino, Lorenzo Santini, Concetta Rafaniello, Cristina Scavone, Francesco Rossi, Liberato Berrino, Konrad Urbanek, Antonella De Angelis
BACKGROUND AND PURPOSE: Doxorubicin (DOXO) is a highly effective anticancer drug but its clinical application is impeded by cardiotoxicity. Asymptomatic diastolic dysfunction can be the earliest manifestation of DOXO cardiotoxicity. Therefore, a search for therapeutic intervention that can interfere with early manifestations and possibly prevent late cardiotoxicity is warranted. Increased DOXO-dependent reactive oxygen species may explain, in part, Ca(2+) and Na(+) overload that contributes to diastolic dysfunction and development of heart failure...
March 20, 2017: British Journal of Pharmacology
https://www.readbyqxmd.com/read/28314848/effects-of-late-sodium-current-blockade-on-ventricular-refibrillation-in-a-rabbit-model
#16
Mohammed Ali Azam, Nima Zamiri, Stéphane Massé, Marjan Kusha, Patrick F H Lai, Govind K Nair, Nigel S Tan, Christopher Labos, Kumaraswamy Nanthakumar
BACKGROUND: After defibrillation of initial ventricular fibrillation (VF), it is crucial to prevent refibrillation to ensure successful resuscitation outcomes. Inability of the late Na(+) current to inactivate leads to intracellular Ca(2+) dysregulation and arrhythmias. Our aim was to determine the effects of ranolazine and GS-967, inhibitors of the late Na(+) current, on ventricular refibrillation. METHODS AND RESULTS: Long-duration VF was induced electrically in Langendorff-perfused rabbit hearts (n=22) and terminated with a defibrillator after 6 minutes...
March 2017: Circulation. Arrhythmia and Electrophysiology
https://www.readbyqxmd.com/read/28255011/ranolazine-prevents-phenotype-development-in-a-mouse-model-of-hypertrophic-cardiomyopathy
#17
Raffaele Coppini, Luca Mazzoni, Cecilia Ferrantini, Francesca Gentile, Josè Manuel Pioner, Tina Laurino, Lorenzo Santini, Valentina Bargelli, Matteo Rotellini, Gianluca Bartolucci, Claudia Crocini, Leonardo Sacconi, Chiara Tesi, Luiz Belardinelli, Jil Tardiff, Alessandro Mugelli, Iacopo Olivotto, Elisabetta Cerbai, Corrado Poggesi
BACKGROUND: Current therapies are ineffective in preventing the development of cardiac phenotype in young carriers of mutations associated with hypertrophic cardiomyopathy (HCM). Ranolazine, a late Na(+) current blocker, reduced the electromechanical dysfunction of human HCM myocardium in vitro. METHODS AND RESULTS: To test whether long-term treatment prevents cardiomyopathy in vivo, transgenic mice harboring the R92Q troponin-T mutation and wild-type littermates received an oral lifelong treatment with ranolazine and were compared with age-matched vehicle-treated animals...
March 2017: Circulation. Heart Failure
https://www.readbyqxmd.com/read/28213480/common-genetic-variant-risk-score-is-associated-with-drug-induced-qt-prolongation-and-torsade-de-pointes-risk-a-pilot-study
#18
David G Strauss, Jose Vicente, Lars Johannesen, Ksenia Blinova, Jay W Mason, Peter Weeke, Elijah R Behr, Dan M Roden, Ray Woosley, Gulum Kosova, Michael A Rosenberg, Christopher Newton-Cheh
BACKGROUND: Drug-induced QT interval prolongation, a risk factor for life-threatening ventricular arrhythmias, is a potential side effect of many marketed and withdrawn medications. The contribution of common genetic variants previously associated with baseline QT interval to drug-induced QT prolongation and arrhythmias is not known. METHODS: We tested the hypothesis that a weighted combination of common genetic variants contributing to QT interval at baseline, identified through genome-wide association studies, can predict individual response to multiple QT-prolonging drugs...
April 4, 2017: Circulation
https://www.readbyqxmd.com/read/28185917/increment-of-late-sodium-currents-in-the-left-atrial-myocytes-and-its-potential-contribution-to-increased-susceptibility-of-atrial-fibrillation-in-castrated-male-mice
#19
Yang Zhang, Hui-Min Wang, Ying-Zhe Wang, Yi-Yuan Zhang, Xue-Xin Jin, Yue Zhao, Jin Wang, Yi-Lin Sun, Gen-Long Xue, Peng-Hui Li, Qi-He Huang, Bao-Feng Yang, Zhen-Wei Pan
BACKGROUND: The incidence of atrial fibrillation (AF) is correlated with decreased levels of testosterone in elderly men. Late sodium current may exert a role in AF pathogenesis. OBJECTIVE: The purpose of this study was to explore the effect of testosterone deficiency on AF susceptibility and the therapeutic effect of late sodium current inhibitors in mice. METHODS: Male ICR mice (5 weeks old) were castrated to establish a testosterone deficiency model...
February 6, 2017: Heart Rhythm: the Official Journal of the Heart Rhythm Society
https://www.readbyqxmd.com/read/28182279/ranolazine-added-to-amiodarone-facilitates-earlier-conversion-of-atrial-fibrillation-compared-to-amiodarone-only-therapy
#20
Nikos Tsanaxidis, Isaac Aidonidis, Apostolia Hatziefthimiou, Stella S Daskalopoulou, Grigorios Giamouzis, Filippos Triposkiadis, Ioannis Skoularigis
BACKGROUND: Amiodarone (AMIO) is for many years effectively used to control ventricular rate during atrial fibrillation (AF) and to convert it into sinus rhythm. However, due to its delayed onset of action, ranolazine (RAN), a new antianginal agent with atrial-selective electrophysiologic properties, has recently been attempted as add-on therapy with AMIO to facilitate AF conversion. METHODS: To establish the role of this combination therapy, we enrolled 173 consecutive patients (68 ± 10 years, 54% male) with recent-onset (<48-hour duration) AF who were eligible for pharmacologic cardioversion...
February 9, 2017: Pacing and Clinical Electrophysiology: PACE
keyword
keyword
53609
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"